Acadia, page-652

Some of the positions being currently advertised by Acadia suggest to me a probable connection with NNZ-2591 development.

Executive Director Portfolio Management Rare Disease

Responsibilities include:

Co-chair stage-gate committee post-Phase 1 for Rare Disease franchise.

Lead and facilitate decision analysis including development and assessment of outcome scenarios with alternative development options, robust go/no go decision criteria, probability of technical and regulatory success (PTRS), and value and investment implications.

Proactively communicate contract milestones, scientific and financial obligations to Asset Strategy Teams for partnered programs to make well-informed strategic recommendations and decisions.

Co-ordinate formation of Asset Strategy Teams for Rare Disease Franchise programs following a Go to Phase 2 (POC) decision at Stage Gate 3 and knowledge transfer from the Early-Stage AST members or Alliance Delivery Teams (ADTs) for partnered programs.

https://acadia.com/careers/job-board/job/?gh_jid=7329272002


Associate Director Analytical Development Drug Product

Responsibilities include:

Oversight of the outsourced analytical development activities associated with the development, validation, technology transfer, and line extension of drug product.

Develops and validates analytical methods for small molecules in various dosage forms.

https://acadia.com/careers/job-board/job/?gh_jid=7297102002